Kefort

Ibandronic Acid, the active ingredient in Kefort, is a bisphosphonate presented as an oral tablet for oral use. It treats osteoporosis and Paget's disease of bone in adult patients and is indicated for the management of postmenopausal osteoporosis, male osteoporosis, and for reducing bone turnover in Paget's disease.

GNH USA supplies Kefort as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU Good Manufacturing Practice and provides regulatory‑approved products to healthcare providers across global markets.

Kefort (ibandronic acid) is used in conditions affecting bone remodeling and density.

Osteoporosis (postmenopausal women): improves bone mineral density and reduces fracture risk. Osteoporosis (men): increases bone strength and lowers fracture incidence. Paget's disease of bone: normalizes abnormal bone turnover and alleviates bone pain.

Oral ibandronic acid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Abdominal pain - Nausea - Dyspepsia - Musculoskeletal pain

Serious or Rare Side Effects: - Osteonecrosis of the jaw - Atypical femur fracture - Severe esophagitis

Before initiating therapy, several safety considerations should be observed. - Assess renal function: evaluate creatinine clearance to ensure suitability. - Ensure adequate calcium and vitamin D intake: supplement as needed to maintain normal levels. - Avoid concomitant oral bisphosphonates: reduces risk of cumulative toxicity. - Monitor for esophageal irritation: advise patients to remain upright after dosing. - Review use of NSAIDs or steroids: may increase gastrointestinal risk. - Store at below 25°C: keep in the original pack, protect from moisture.

Ibandronic acid can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Antacids or supplements containing calcium, magnesium, aluminum, or iron taken within 2 hours: markedly reduces ibandronate absorption. - Concomitant use with other bisphosphonates: increases risk of cumulative toxicity. - Severe renal impairment (eGFR < 30 mL/min): contraindicated due to accumulation risk.

Moderate Interactions (Monitor Closely): - Calcium supplements (timing separate by ≥2 hours). - Vitamin D analogs (may enhance calcium effects). - Corticosteroids (increase risk of osteoporosis). - Warfarin (potential alteration of INR). - Diuretics (affect calcium balance).